BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND DEK, D6S231E, 7913, ENSG00000124795, P35659
25 results:

  • 1. dek oncoprotein participates in heterochromatin replication via SUMO-dependent nuclear bodies.
    Pierzynska-Mach A; Czada C; Vogel C; Gwosch E; Osswald X; Bartoschek D; Diaspro A; Kappes F; Ferrando-May E
    J Cell Sci; 2023 Dec; 136(23):. PubMed ID: 37997922
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Imaging-based study demonstrates how the dek nanoscale distribution differentially correlates with epigenetic marks in a breast cancer model.
    Pierzynska-Mach A; Cainero I; Oneto M; Ferrando-May E; Lanzanò L; Diaspro A
    Sci Rep; 2023 Aug; 13(1):12749. PubMed ID: 37550322
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia).
    Wood CR; Wu WT; Yang YS; Yang JS; Xi Y; Yang WJ
    Adv Cancer Res; 2023; 158():199-231. PubMed ID: 36990533
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Role of dek in carcinogenesis, diagnosis, prognosis, and therapeutic outcome of breast cancer: An evidence-based clinical review.
    Habiburrahman M; Sutopo S; Wardoyo MP
    Crit Rev Oncol Hematol; 2023 Jan; 181():103897. PubMed ID: 36535490
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. NMR-based metabolomic analysis identifies RON-dek-β-catenin dependent metabolic pathways and a gene signature that stratifies breast cancer patient survival.
    Vicente-Muñoz S; Hunt BG; Lange TE; Wells SI; Waltz SE
    PLoS One; 2022; 17(9):e0274128. PubMed ID: 36067206
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Exosomal dek removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells.
    Yang YS; Jia XZ; Lu QY; Cai SL; Huang XT; Yang SH; Wood C; Wang YH; Zhou JJ; Chen YD; Yang JS; Yang WJ
    Oncogene; 2022 Apr; 41(18):2624-2637. PubMed ID: 35351996
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Next-generation sequencing identifies recurrent copy number variations in invasive breast carcinomas from Ghana.
    Anwar T; Rufail ML; Djomehri SI; Gonzalez ME; Lazo de la Vega L; Tomlins SA; Newman LA; Kleer CG
    Mod Pathol; 2020 Aug; 33(8):1537-1545. PubMed ID: 32152520
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Association of Genomic Domains in
    Patel VL; Busch EL; Friebel TM; Cronin A; Leslie G; McGuffog L; Adlard J; Agata S; Agnarsson BA; Ahmed M; Aittomäki K; Alducci E; Andrulis IL; Arason A; Arnold N; Artioli G; Arver B; Auber B; Azzollini J; Balmaña J; Barkardottir RB; Barnes DR; Barroso A; Barrowdale D; Belotti M; Benitez J; Bertelsen B; Blok MJ; Bodrogi I; Bonadona V; Bonanni B; Bondavalli D; Boonen SE; Borde J; Borg A; Bradbury AR; Brady A; Brewer C; Brunet J; Buecher B; Buys SS; Cabezas-Camarero S; Caldés T; Caliebe A; Caligo MA; Calvello M; Campbell IG; Carnevali I; Carrasco E; Chan TL; Chu ATW; Chung WK; Claes KBM; Collaborators GS; Collaborators E; Cook J; Cortesi L; Couch FJ; Daly MB; Damante G; Darder E; Davidson R; de la Hoya M; Puppa LD; Dennis J; Díez O; Ding YC; Ditsch N; Domchek SM; Donaldson A; Dworniczak B; Easton DF; Eccles DM; Eeles RA; Ehrencrona H; Ejlertsen B; Engel C; Evans DG; Faivre L; Faust U; Feliubadaló L; Foretova L; Fostira F; Fountzilas G; Frost D; García-Barberán V; Garre P; Gauthier-Villars M; Géczi L; Gehrig A; Gerdes AM; Gesta P; Giannini G; Glendon G; Godwin AK; Goldgar DE; Greene MH; Gutierrez-Barrera AM; Hahnen E; Hamann U; Hauke J; Herold N; Hogervorst FBL; Honisch E; Hopper JL; Hulick PJ; Investigators K; Investigators H; Izatt L; Jager A; James P; Janavicius R; Jensen UB; Jensen TD; Johannsson OT; John EM; Joseph V; Kang E; Kast K; Kiiski JI; Kim SW; Kim Z; Ko KP; Konstantopoulou I; Kramer G; Krogh L; Kruse TA; Kwong A; Larsen M; Lasset C; Lautrup C; Lazaro C; Lee J; Lee JW; Lee MH; Lemke J; Lesueur F; Liljegren A; Lindblom A; Llovet P; Lopez-Fernández A; Lopez-Perolio I; Lorca V; Loud JT; Ma ESK; Mai PL; Manoukian S; Mari V; Martin L; Matricardi L; Mebirouk N; Medici V; Meijers-Heijboer HEJ; Meindl A; Mensenkamp AR; Miller C; Gomes DM; Montagna M; Mooij TM; Moserle L; Mouret-Fourme E; Mulligan AM; Nathanson KL; Navratilova M; Nevanlinna H; Niederacher D; Nielsen FCC; Nikitina-Zake L; Offit K; Olah E; Olopade OI; Ong KR; Osorio A; Ott CE; Palli D; Park SK; Parsons MT; Pedersen IS; Peissel B; Peixoto A; Pérez-Segura P; Peterlongo P; Petersen AH; Porteous ME; Pujana MA; Radice P; Ramser J; Rantala J; Rashid MU; Rhiem K; Rizzolo P; Robson ME; Rookus MA; Rossing CM; Ruddy KJ; Santos C; Saule C; Scarpitta R; Schmutzler RK; Schuster H; Senter L; Seynaeve CM; Shah PD; Sharma P; Shin VY; Silvestri V; Simard J; Singer CF; Skytte AB; Snape K; Solano AR; Soucy P; Southey MC; Spurdle AB; Steele L; Steinemann D; Stoppa-Lyonnet D; Stradella A; Sunde L; Sutter C; Tan YY; Teixeira MR; Teo SH; Thomassen M; Tibiletti MG; Tischkowitz M; Tognazzo S; Toland AE; Tommasi S; Torres D; Toss A; Trainer AH; Tung N; van Asperen CJ; van der Baan FH; van der Kolk LE; van der Luijt RB; van Hest LP; Varesco L; Varon-Mateeva R; Viel A; Vierstraete J; Villa R; von Wachenfeldt A; Wagner P; Wang-Gohrke S; Wappenschmidt B; Weitzel JN; Wieme G; Yadav S; Yannoukakos D; Yoon SY; Zanzottera C; Zorn KK; D'Amico AV; Freedman ML; Pomerantz MM; Chenevix-Trench G; Antoniou AC; Neuhausen SL; Ottini L; Nielsen HR; Rebbeck TR
    Cancer Res; 2020 Feb; 80(3):624-638. PubMed ID: 31723001
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Optical Redox Imaging Detects the Effects of dek Oncogene Knockdown on the Redox State of MDA-MB-231 breast cancer Cells.
    Wen Y; Xu HN; Privette Vinnedge L; Feng M; Li LZ
    Mol Imaging Biol; 2019 Jun; 21(3):410-416. PubMed ID: 30758703
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The unique dek oncoprotein in women's health: A potential novel biomarker.
    de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
    Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Silencing dek downregulates cervical cancer tumorigenesis and metastasis via the dek/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
    Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
    Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer.
    Delaunay S; Rapino F; Tharun L; Zhou Z; Heukamp L; Termathe M; Shostak K; Klevernic I; Florin A; Desmecht H; Desmet CJ; Nguyen L; Leidel SA; Willis AE; Büttner R; Chariot A; Close P
    J Exp Med; 2016 Oct; 213(11):2503-2523. PubMed ID: 27811057
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The dek oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
    Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
    Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. dek: A novel early screening and prognostic marker for breast cancer.
    Ying G; Wu Y
    Mol Med Rep; 2015 Nov; 12(5):7491-5. PubMed ID: 26459608
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.
    Witkiewicz AK; Balaji U; Knudsen ES
    Clin Cancer Res; 2014 Sep; 20(18):4837-48. PubMed ID: 25047707
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The dek oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
    Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
    Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. National Surgical Adjuvant breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.
    McCaskill-Stevens W; Wilson JW; Cook ED; Edwards CL; Gibson RV; McElwain DL; Figueroa-Moseley CD; Paskett ED; Roberson NL; Wickerham DL; Wolmark N
    Clin Trials; 2013 Apr; 10(2):280-91. PubMed ID: 23335675
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The dek oncogene is a target of steroid hormone receptor signaling in breast cancer.
    Privette Vinnedge LM; Ho SM; Wikenheiser-Brokamp KA; Wells SI
    PLoS One; 2012; 7(10):e46985. PubMed ID: 23071688
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. dek overexpression is correlated with the clinical features of breast cancer.
    Liu S; Wang X; Sun F; Kong J; Li Z; Lin Z
    Pathol Int; 2012 Mar; 62(3):176-81. PubMed ID: 22360505
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The human dek oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
    Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
    Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.